Katrekar, Dhruva
Yen, James
Xiang, Yichen
Saha, Anushka
Meluzzi, Dario
Savva, Yiannis
Mali, Prashant http://orcid.org/0000-0002-3383-1287
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (R01HG009285, R01HG009285, R01HG009285, R01HG009285, R01HG009285, R01HG009285)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (RO1CA222826)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (RO1GM123313)
Article History
Received: 15 January 2021
Accepted: 24 November 2021
First Online: 10 February 2022
Competing interests
: D.K., J.Y. and P.M. have filed patents based on this work. P.M. is a scientific co-founder of Shape Therapeutics, Boundless Biosciences, Navega Therapeutics and Engine Biosciences. The terms of these arrangements have been reviewed and approved by the University of California, San Diego in accordance with its conflict of interest policies. Y.S. is an employee of Shape Therapeutics. D.K. is now an employee of Shape Therapeutics. The remaining authors declare no competing interests.